A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus.

[1]  B. Collins,et al.  Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  N. West,et al.  Pregnancy in cystic fibrosis: Review of the literature and expert recommendations. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  D. Kay,et al.  Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  J. Taylor-Cousar,et al.  Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  S. Nevitt,et al.  Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). , 2020, The Cochrane database of systematic reviews.

[6]  D. Sharma,et al.  Making neonatal intensive care: cost effective , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[7]  P. Negulescu,et al.  In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis , 2019, Science Translational Medicine.

[8]  M. Rosenfeld,et al.  Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. , 2018, The Lancet. Respiratory medicine.

[9]  R. Houwen,et al.  Meconium ileus in Cystic Fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[10]  M. Rosenberg,et al.  Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis , 2016, Pediatric pulmonology.

[11]  W. T. Harris,et al.  Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. , 2016, The Lancet. Respiratory medicine.

[12]  D. Borowitz,et al.  A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. , 2012, Journal of pediatric surgery.

[13]  Jason C. Fisher,et al.  Neonatal outcomes associated with intestinal abnormalities diagnosed by fetal ultrasound. , 2009, Journal of pediatric surgery.

[14]  S. Engum,et al.  Surgical considerations in cystic fibrosis: a 32-year evaluation of outcomes. , 2005, Surgery.

[15]  L. Sirota,et al.  Faecal elastase 1 levels in premature and full term infants , 2003, Archives of disease in childhood. Fetal and neonatal edition.

[16]  J. Estroff,et al.  Prevalence of cystic fibrosis in fetuses with dilated bowel. , 1992, Radiology.